WEBINAR - The AI Advantage:

Game-Changing Insights in HCS with Cell Painting

Don't miss our webinar featuring experts from Ardigen and Janssen Pharmaceutica. Together, we'll present the transformative impact of AI on High Content Screening and Cell Painting, driving the future of drug discovery.

Access the webinar

What Will You Gain From This Webinar?

  1. Integrating HCS, Cell Painting & AI

    Dive into how to integrate High Content Screening Cell Painting Assay with AI to revolutionize drug discovery.

  2. Diving Deep with AI Insights

    Understand the depth of insights AI can provide from Cell Painting data.

  3. AI Pipeline Essentials

    Discover the key components for building a reliable AI pipeline and how to ensure data quality.

  4. Expert Insights from Ardigen and Janssen Pharmaceutica

    Benefit from real-world examples and best practices shared by industry leaders.






About the webinar


In the dynamic world of drug discovery, Artificial Intelligence and techniques like High Content Screening (HCS), especially image-based morphological profiling with Cell Painting Assay, aren't just innovations – they are game-changers. This webinar is your guide to unlocking the potential of these tools, both from a business standpoint and a scientific perspective.

By integrating Cell Painting and Artificial Intelligence, tasks like drug repurposing, virtual screening, or off-target activity detection can be accelerated. That's why we will demonstrate how to implement them successfully in a drug discovery pipeline to make it more efficient and effective. This isn't just about getting to the market faster, but doing so with more accuracy and insight.

Furthermore, we'll explore the practical advantages of an AI-based pipeline in predicting chemical and biological properties. Beyond the clear cost and risk benefits, it's our belief that understanding AI's capabilities and limitations is vital to making informed decisions in the field.

Our session will wrap up with a Q&A segment, offering you a chance to dive deeper into any specific areas of interest or concerns.

Join us for a comprehensive look into the future of drug discovery, where cutting-edge tools meet a real-world application.

Meet our speakers:
Emmanuel Gustin, PhD
Principal Scientist, Janssen Pharmaceutica

Dr. Emmanuel Gustin obtained a PhD in experimental physics in 1995 and started working in the pharmaceutical industry after he joined Johnson & Johnson in 2000. There he took up roles in data analysis, image analysis, drug discovery technology development, and information management. He has been active in the field of high-content imaging since 2006, with a focus on maximizing data extraction from images and turning it into actionable information for drug discovery teams. Currently, he is a Principal Scientist in the Discovery Technologies & Molecular Pharmacology team, which operates one of the world’s most powerful high-content imaging platforms. His responsibilities include supporting projects in Janssen’s therapeutic areas, developing algorithmic solutions, and guiding platform development. He is based in Beerse, Belgium.

Anna Bracha
Data Scientist, Computer Vision Specialist, Ardigen

Anna Bracha is a Data Scientist III at Ardigen. She graduated in Automation Control and Robotics from AGH with a specialization in Intelligent Control Systems. At Ardigen for nearly 3.5 years, she has worked on various projects spanning Data Science and machine learning engineering. Anna's multifaceted experience has equipped her with a unique perspective, allowing her to effectively tackle challenges and drive innovation in her projects. Working on different kinds of problems, she has gained deep insight into leveraging most out of high-content images and Cell Profiler features. Anna’s domain knowledge allows her to apply novel machine learning techniques within the biomedical imaging field.

Magdalena Otrocka, PhD
Lead Molecular Biologist, Ardigen

Magdalena is a seasoned biotechnologist with over two decades of experience in cell biology, assay development, and high-content screening. With a strong background in cell-based phenotypic screening, she has worked on a wide range of projects across various therapeutic areas, such as oncology, neurodegenerative disorders, and infectious diseases. Throughout her career, Magdalena has collaborated with professionals from diverse fields, including chemists, in-vivo biologists, and computational scientists. As a high-throughput microscopy enthusiast, she has been responsible for establishing and managing high-content screening platforms, overseeing all aspects of high-content activities, including education and training. Currently, Magdalena serves as the Lead Molecular Biologist at Ardigen. In this role, she focuses on delivering biologically relevant results to clients through close collaboration with data scientists and manages scientific collaborations to ensure effective teamwork and successful project outcomes.

See Our Latest Talk